Key facts
- This page summarizes Eugene Bauer's Form 4 filing for Evommune, Inc..
- 3 reported transactions and 2 derivative rows are listed below.
- Filing timestamp: 12 Nov 2025, 16:15.
Eugene Bauer - 07 Nov 2025 Form 4 Insider Report for Evommune, Inc.
- Signature
- /s/ Gregory S. Moss, Attorney-in-Fact
- Issuer symbol
- EVMN on NYSE
- Transactions as of
- 07 Nov 2025
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 12 Nov 2025, 16:15:24 UTC
- Previous filing
- 05 Nov 2025
- Next filing
- 19 Dec 2025
- SEC
- View on sec.gov
Key filing fact
Eugene Bauer filed Form 4 for Evommune, Inc. on 12 Nov 2025.
Change
- Previous filing in this sequence was filed on 05 Nov 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001678620
Primary reporting owner
Bauer Eugene
- Relationship
- Chief Medical Officer, Director
- Address
- C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO
- Signature
- /s/ Gregory S. Moss, Attorney-in-Fact
- Signature date
- 12 Nov 2025
Transactions Table
EVMN
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +25,812
- Change %
- +10%
- Price
- Shares after
- 272,296
- Date
- 07 Nov 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
EVMN
transaction
Derivative
Series Seed Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -206,355
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,225
- Exercise price
- Footnotes
- F1
EVMN
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -12,500
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,587
- Exercise price
- Footnotes
- F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date. |
| F2 | Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date. |